“A game changer in diagnostics? New technology changes viewpoint on infections…”
Global Market Analysis with Forecasts by Applications, Technologies, Product and User. With Executive and Consultant Guides. 2025 to 2029"
Howe Sound Research Published January 2024 – 364 pages
Unlimited growth potential? A Game Changer? It is not exaggeration. Metagenomic assays could change the way medical treatment is done. Learn all about it in this new research report.
The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower costs is driving a new type of genetic testing. Metagenomic Testing looks at all the genetic material in a sample. In the process it learns about infection, cancer, antimicrobial resistance, and the patient genome. It’s a whole new approach. Chronic infection? Find out the real culprits. Secrets of the microbiome and gut health? Metagenomics has the answers. In everything from human medical treatment to wastewater studies this new approach is creating startling answers. And finding new kinds of organisms and pathogens in the process. Already some minor medical miracles have been accomplished. This report looks at the technology, the applications, the users and the types of products that will be sold. The report includes detailed breakouts for 14 countries and 5 regions.
Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don’t worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
1 Market Guides …………………………………………………………………………………………………… 18
1.1 Strategic Situation Analysis …………………………………………………………………………………. 19
1.2 Guide for Executives and Business Development Staff …………………………………………. 21
1.3 Guide for Management Consultants and Investment Advisors …………………………….. 22
2 Introduction and Market Definition …………………………………………………………………….. 23
2.1 What is Metagenomics? …………………………………………………………………………………….. 24
2.2 Market Definition ……………………………………………………………………………………………….. 26
2.2.1 Revenue Market Size. ……………………………………………………………………………………… 26
2.2.2 Clinical …………………………………………………………………………………………………………… 27
2.2.3 Microbiome……………………………………………………………………………………………………. 27
2.2.4 Agricultural …………………………………………………………………………………………………….. 27
2.2.5 Environmental & Other …………………………………………………………………………………… 27
2.3 Methodology …………………………………………………………………………………………………….. 28
2.3.1 Methodology …………………………………………………………………………………………………. 28
2.3.2 Sources ………………………………………………………………………………………………………….. 28
2.3.3 Authors ………………………………………………………………………………………………………….. 28
2.4 Perspective: Healthcare and the IVD Industry …………………………………………………….. 30
2.4.1 Global Healthcare Spending ………………………………………………………………………….. 30
2.4.2 Spending on Diagnostics ………………………………………………………………………………… 31
2.4.3 Important Role of Insurance for Diagnostics …………………………………………………….. 33
2.5 Chromosomes, Genes and Epigenetics ………………………………………………………………. 34
2.5.1 Chromosomes ……………………………………………………………………………………………….. 34
2.5.2 Genes ……………………………………………………………………………………………………………. 36
2.5.3 Epigenetics ……………………………………………………………………………………………………. 39
3 Market Overview ……………………………………………………………………………………………….. 41
3.1 Players in a Dynamic Market ………………………………………………………………………………. 42
3.1.1 Academic Research Lab ……………………………………………………………………………….. 43
3.1.2 Diagnostic Test Developer ………………………………………………………………………………. 43
3.1.3 Instrumentation Supplier …………………………………………………………………………………. 44
3.1.4 Chemical/Reagent Supplier ……………………………………………………………………………. 44
3.1.5 Pathology Supplier …………………………………………………………………………………………. 44
3.1.6 Independent Clinical Laboratory ……………………………………………………………………. 45
3.1.7 Public National/regional Laboratory ……………………………………………………………….. 45
3.1.8 Hospital Laboratory ………………………………………………………………………………………… 46
3.1.9 Physicians Office Lab (POLS) …………………………………………………………………………… 46
3.1.10 Audit Body ………………………………………………………………………………………………….. 47
3.1.11 Certification Body ……………………………………………………………………………………….. 47
3.2 Metagenomics Applications ………………………………………………………………………………. 49
3.2.1 Clinical Metagenomics …………………………………………………………………………………… 49
3.2.2 Diagnostic Use ……………………………………………………………………………………………….. 49
3.2.3 Syndromic Multiplex vs. Metagenomic Testing …………………………………………………. 50
3.2.4 Antimicrobial Resistance ………………………………………………………………………………… 52
3.2.5 Managing the Microbiome …………………………………………………………………………….. 52
3.2.6 Public Health Use ……………………………………………………………………………………………. 52
3.3 Clinical Industry Structure …………………………………………………………………………………… 53
3.3.1 Hospital’s Testing Share …………………………………………………………………………………… 53
3.3.2 Economies of Scale ………………………………………………………………………………………… 53
3.3.3 Hospital vs. Central Lab ………………………………………………………………………………….. 54
3.3.4 Physician Office Lab’s …………………………………………………………………………………….. 55
3.3.5 Physician’s and POCT …………………………………………………………………………………….. 55
4 Market Trends ……………………………………………………………………………………………………. 56
4.1 Factors Driving Growth ………………………………………………………………………………………. 57
4.1.1 A New Approach to Diagnostics …………………………………………………………………….. 57
4.1.2 The Aging Effect …………………………………………………………………………………………….. 58
4.1.3 The Known and the Unknown …………………………………………………………………………. 61
4.1.4 A Research Bonanza ………………………………………………………………………………………. 61
4.2 Factors Limiting Growth ……………………………………………………………………………………… 62
4.2.1 Increased Competition Lowers Price ……………………………………………………………….. 62
4.2.2 Lower Costs ……………………………………………………………………………………………………. 63
4.2.3 Testing usage analysis curtailing growth ………………………………………………………….. 63
4.2.4 Wellness has a downside ………………………………………………………………………………… 63
4.3 Instrumentation, Automation and Diagnostic Trends …………………………………………… 65
4.3.1 Traditional Automation and Centralization ………………………………………………………. 65
4.3.2 The New Automation, Decentralization and Point of Care ……………………………….. 65
4.3.3 Instruments Key to Market Share ……………………………………………………………………… 67
4.3.4 Bioinformatics Plays a Role ……………………………………………………………………………… 67
4.3.5 PCR Takes Command …………………………………………………………………………………….. 68
4.3.6 Next Generation Sequencing Fuels a Revolution ……………………………………………… 69
4.3.7 NGS Impact on Pricing ……………………………………………………………………………………. 70
4.3.8 Whole Genome Sequencing, A Brave New World …………………………………………… 70
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment …………………………………… 71
4.3.10 Shifting Role of Diagnostics ………………………………………………………………………….. 72
5 Metagenomics Recent Developments ……………………………………………………………….. 74
5.1 Recent Developments ……………………………………………………………………………………….. 75
5.1.1 Importance of This Section ……………………………………………………………………………… 75
5.1.2 How to Use This Section …………………………………………………………………………………… 75
5.2 Delve Bio Showing Delivers Greater Diagnostic Yield …………………………………………… 75
5.3 Sewage metagenomics potentially allows surveillance ……………………………………….. 76
5.4 Rapid metagenomics to reduce AMR and sepsis ………………………………………………… 77
5.5 UK and U.S. Use Metagenomics for Biothreat Assessment …………………………………….. 80
5.6 Phase Genomics Metagenomics Innovation Award ……………………………………………. 83
5.7 New Method for Human Gut Assessment ……………………………………………………………. 85
5.8 Metagenomic sequencing Used for Pneumonia Care ………………………………………… 88
5.9 Sepsis Study Shows Metagenomic Clinical Value ………………………………………………… 90
5.10 Delve Bio to Develop Metagenomic Sequencing Dx …………………………………………… 93
5.11 Metagenomics Could be a Game-changer ……………………………………………………….. 95
5.12 Model Predicts Millions of Metagenomic Proteins ………………………………………………… 97
5.13 Microbiome Analysis May Yield False Results ……………………………………………………….. 98
5.14 Gut microbiome at center of Parkinson’s disease ………………………………………………. 101
5.15 MicroGenDx, Evvy Partner for Metagenomic Test ……………………………………………… 104
5.16 Diagnostic accuracy of metagenomic NGS ……………………………………………………… 105
5.17 Metagenomics implicates the gut microbiome …………………………………………………. 106
5.18 Charities Award $2M for Metagenomic Pathogen Research ……………………………… 106
5.19 Cost-effective metagenomic HiFi sequencing …………………………………………………… 107
5.20 Microbiome Links Uncovered ……………………………………………………………………………. 109
5.21 Metagenomi Named an Endpoints 11 Winner …………………………………………………… 111
5.22 Biotia Raises $8M in Series A Financing ………………………………………………………………. 112
6 Profiles of Key Companies ………………………………………………………………………………… 114
6.1 Arc Bio …………………………………………………………………………………………………………….. 115
6.2 BaseClear ………………………………………………………………………………………………………… 116
6.3 BGI Genomics Co. Ltd ……………………………………………………………………………………… 117
6.4 Biome Makers ………………………………………………………………………………………………….. 119
6.5 bioMérieux Diagnostics …………………………………………………………………………………….. 120
6.6 Bio-Rad Laboratories, Inc………………………………………………………………………………….. 123
6.7 CosmosID ………………………………………………………………………………………………………… 125
6.8 Element Biosciences ………………………………………………………………………………………… 126
6.9 Fusion Genomics. …………………………………………………………………………………………….. 128
6.10 Helix OpCo ………………………………………………………………………………………………………. 129
6.11 Illumina ……………………………………………………………………………………………………………. 130
6.12 Institute for Metagenomics ……………………………………………………………………………….. 131
6.13 Karius ………………………………………………………………………………………………………………. 132
6.14 Metabiomics Corp …………………………………………………………………………………………… 134
6.15 Metagenomi ……………………………………………………………………………………………………. 135
6.16 MetaSUB International Consortium ……………………………………………………………………. 136
6.17 Microbiome Insights …………………………………………………………………………………………. 137
6.18 MicroGenDx …………………………………………………………………………………………………….. 138
6.19 Molecular Stethoscope ……………………………………………………………………………………. 139
6.20 Norgen Biotek Corp. ………………………………………………………………………………………… 141
6.21 Noscendo ……………………………………………………………………………………………………….. 142
6.22 Novogene Bioinformatics Technology Co., Ltd. …………………………………………………. 143
6.23 One Codex ……………………………………………………………………………………………………… 145
6.24 OraSure Technologies ………………………………………………………………………………………. 146
6.25 Oxford Nanopore Technologies ……………………………………………………………………….. 148
6.26 Pacific Biosciences …………………………………………………………………………………………… 149
6.27 PathoQuest S.A. ………………………………………………………………………………………………. 150
6.28 Perkin Elmer ……………………………………………………………………………………………………… 151
6.29 Promega …………………………………………………………………………………………………………. 153
6.30 Qiagen ……………………………………………………………………………………………………………. 155
6.31 Second Genome …………………………………………………………………………………………….. 157
6.32 Siemens Healthineers ……………………………………………………………………………………….. 158
6.33 Sysmex …………………………………………………………………………………………………………….. 160
6.34 Takara Bio ……………………………………………………………………………………………………….. 163
6.35 Ultima Genomics ……………………………………………………………………………………………… 164
6.36 Zymo Research Corp ……………………………………………………………………………………….. 165
7 Global Market Size …………………………………………………………………………………………… 166
7.1 Global Market by Country ………………………………………………………………………………… 167
7.1.1 Table – Global Market by Country …………………………………………………………………. 167
7.1.2 Chart – Country Market Shares ……………………………………………………………………… 168
7.2 Global Market by Application ………………………………………………………………………….. 169
7.2.1 Table – Global Market by Application …………………………………………………………… 169
7.2.2 Chart – Application Share by Year ………………………………………………………………… 170
7.2.3 Chart – Application Segment Growth Rates ………………………………………………….. 171
7.2.4 Chart – Application Segment Share Shifts ………………………………………………………. 172
7.2.5 Chart – Application Segment Share Base Year ………………………………………………. 173
7.2.6 Chart – Application Segment Share Final Year ………………………………………………. 174
7.3 Global Market by Technology ………………………………………………………………………….. 175
7.3.1 Table – Global Market by Technology …………………………………………………………… 175
7.3.2 Chart – Technology Share by Year ………………………………………………………………… 176
7.3.3 Chart – Technology Segment Growth Rates ………………………………………………….. 177
7.3.4 Chart – Technology Segment Share Shifts………………………………………………………. 178
7.3.5 Chart – Technology Segment Share Base Year ………………………………………………. 179
7.3.6 Chart – Technology Segment Share Final Year ………………………………………………. 180
7.4 Global Market by Product ………………………………………………………………………………… 181
7.4.1 Table – Global Market by Product …………………………………………………………………. 181
7.4.2 Chart – Product Share by Year………………………………………………………………………. 182
7.4.3 Chart – Product Segment Growth Rates ………………………………………………………… 183
7.4.4 Chart – Product Segment Share Shifts ……………………………………………………………. 184
7.4.5 Chart – Product Segment Share Base Year ……………………………………………………. 185
7.4.6 Chart – Product Segment Share Final Year …………………………………………………….. 186
7.5 Global Market by User ……………………………………………………………………………………… 187
7.5.1 Table – Global Market by User ………………………………………………………………………. 187
7.5.2 Chart – User Share by Year ……………………………………………………………………………. 188
7.5.3 Chart – User Segment Growth Rates ……………………………………………………………… 189
7.5.4 Chart – User Segment Share Shifts …………………………………………………………………. 190
7.5.5 Chart – User Segment Share Base Year ………………………………………………………….. 191
7.5.6 Chart – User Segment Share Final Year ………………………………………………………….. 192
8 Market Sizes by Application ……………………………………………………………………………… 193
8.1 Clinical Market…………………………………………………………………………………………………. 194
8.1.1 Table Clinical – by Country ……………………………………………………………………………. 194
8.1.2 Chart – Clinical Growth…………………………………………………………………………………. 195
8.2 Microbiome Market …………………………………………………………………………………………. 196
8.2.1 Table Microbiome – by Country …………………………………………………………………….. 196
8.2.2 Chart – Microbiome Growth …………………………………………………………………………. 197
8.3 Agriculture Market …………………………………………………………………………………………… 198
8.3.1 Table Agriculture – by Country ………………………………………………………………………. 198
8.3.2 Chart – Agriculture Growth …………………………………………………………………………… 199
8.4 Industrial & Other Market ………………………………………………………………………………….. 200
8.4.1 Table Industrial & Other – by Country …………………………………………………………….. 200
8.4.2 Chart – Industrial & Other Growth ………………………………………………………………….. 201
9 Market Sizes by Technology ……………………………………………………………………………… 202
9.1 16srRNA Market ……………………………………………………………………………………………….. 203
9.1.1 Table 16srRNA – by Country …………………………………………………………………………… 203
9.1.2 Chart – 16srRNA Growth ……………………………………………………………………………….. 204
9.2 Shotgun Market ……………………………………………………………………………………………….. 205
9.2.1 Table Shotgun – by Country ………………………………………………………………………….. 205
9.2.2 Chart – Shotgun Growth ……………………………………………………………………………….. 206
9.3 WGS Market …………………………………………………………………………………………………….. 207
9.3.1 Table WGS – by Country ……………………………………………………………………………….. 207
9.3.2 WGS – Growth ……………………………………………………………………………………………… 208
9.4 Other Technology Market ………………………………………………………………………………… 209
9.4.1 Table Other Technology – by Country……………………………………………………………. 209
9.4.2 Chart – Other Technology Growth ………………………………………………………………… 210
10 Market Sizes by Product……………………………………………………………………………….. 211
10.1 Instruments Market …………………………………………………………………………………………… 212
10.1.1 Table Instruments – by Country ………………………………………………………………….. 212
10.1.2 Chart – Instrument Growth …………………………………………………………………………. 213
10.2 Reagents and Kits Market…………………………………………………………………………………. 214
10.2.1 Table Reagents and Kits – by Country ………………………………………………………… 214
10.2.2 Chart – Reagents and Kits Growth ……………………………………………………………… 215
10.3 Software Market ………………………………………………………………………………………………. 216
10.3.1 Table Software – by Country ……………………………………………………………………… 216
10.3.2 Software Growth……………………………………………………………………………………….. 217
10.4 Services Market ……………………………………………………………………………………………….. 218
10.4.1 Table Services – by Country ……………………………………………………………………….. 218
10.4.2 Chart – Services Growth ……………………………………………………………………………. 219
11 Market Sizes by User …………………………………………………………………………………….. 220
11.1 Academic Market ……………………………………………………………………………………………. 221
11.1.1 Table Academic – by Country …………………………………………………………………… 221
11.1.2 Chart – Academic Growth ………………………………………………………………………… 222
11.2 Clinical Market…………………………………………………………………………………………………. 223
11.2.1 Table Clinical – by Country ………………………………………………………………………… 223
11.2.2 Chart – Clinical Growth ……………………………………………………………………………… 224
11.3 Pharmaceutical Market ……………………………………………………………………………………. 225
11.3.1 Table Pharmaceutical – by Country …………………………………………………………… 225
11.3.2 Pharmaceutical – Predictive Growth …………………………………………………………. 226
11.4 Other User Market ……………………………………………………………………………………………. 227
11.4.1 Table Other User – by Country ……………………………………………………………………. 227
11.4.2 Chart – Other User Growth ………………………………………………………………………… 228
12 Appendices ………………………………………………………………………………………………… 229
12.1 United States Medicare System: Laboratory Fees Schedule ……………………………….. 229
12.2 The Most Used IVD Assays …………………………………………………………………………………. 352
12.3 The Highest Grossing Assays ……………………………………………………………………………… 357
Table of Tables
Table 1 The Base Pairs………………………………………………………………………………………………………. 37
Table 2 Market Players by Type ……………………………………………………………………………………….. 43
Table 3 The Different Applications of Metagenomic Testing ………………………………………………. 49
Table 4 Factors Driving Growth …………………………………………………………………………………………. 57
Table 5 Four Factors Limiting Growth ………………………………………………………………………………… 62
Table 6 Seven Key Diagnostic Laboratory Technology Trends ……………………………………………. 65
Table 7 Global Market by Country ………………………………………………………………………………….. 167
Table 8 Global Market by Application ……………………………………………………………………………. 169
Table 9 Global Market by Technology ……………………………………………………………………………. 175
Table 10 Global Market by Product ………………………………………………………………………………… 181
Table 11 Global Market by User ……………………………………………………………………………………… 187
Table 12 Clinical Segment by Country ……………………………………………………………………………. 194
Table 13 Microbiome Segment by Country …………………………………………………………………….. 196
Table 14 Agriculture Segment by Country ………………………………………………………………………. 198
Table 15 Industrial & Other Segment by Country ……………………………………………………………… 200
Table 16 16srRNA Segment by Country …………………………………………………………………………… 203
Table 17 Shotgun Segment by Country …………………………………………………………………………… 205
Table 18 WGS Segment by Country ………………………………………………………………………………… 207
Table 19 Other Technology Segment by Country ……………………………………………………………. 209
Table 20 Instruments Segment by Country ………………………………………………………………………. 212
Table 21 Reagents and Kits Segment by Country ……………………………………………………………. 214
Table 22 Software Segment by Country ………………………………………………………………………….. 216
Table 23 Services Segment by Country …………………………………………………………………………… 218
Table 24 Academic Segment by Country ……………………………………………………………………….. 221
Table 25 Clinical Segment by Country ……………………………………………………………………………. 223
Table 26 Pharmaceutical Segment by Country ……………………………………………………………….. 225
Table 27 Other User Segment by Country ……………………………………………………………………….. 227
Table 28 Clinical Lab Fee Schedule ………………………………………………………………………………… 229
Table 29 The Most Common Assays ………………………………………………………………………………… 352
Table 30 Largest Revenue Assays ……………………………………………………………………………………. 357
Table of Figures
Figure 1 Global Health Care Spending ……………………………………………………………………………… 31
Figure 2 The Lab Test Pie ………………………………………………………………………………………………….. 32
Figure 3 DNA Strands and Chromosomes …………………………………………………………………………. 34
Figure 4 Karyogram of Human Chromosomes …………………………………………………………………… 35
Figure 5 Size of Various Genomes …………………………………………………………………………………….. 38
Figure 6 The Road to Diagnostics ……………………………………………………………………………………… 42
Figure 7 The New Diagnostics …………………………………………………………………………………………… 58
Figure 8 The Changing Age of the World Population …………………………………………………………. 59
Figure 9 Health Care Consumption by Age ………………………………………………………………………. 60
Figure 10 Cancer Incidence – Age at Diagnosis ………………………………………………………………… 60
Figure 11 Centralized vs. Decentralized Laboratory Service ………………………………………………. 66
Figure 12 A Highly Multiplexed Syndromic Testing Unit ……………………………………………………….. 66
Figure 13 The Real Cost to Sequence the Human Genome ……………………………………………….. 69
Figure 14 The Codevelopment Process …………………………………………………………………………….. 71
Figure 15 Comparing MDx Diagnostic and Traditional Testing ……………………………………………. 73
Figure 16 Country Market Shares …………………………………………………………………………………….. 168
Figure 17 Application Share by Year ……………………………………………………………………………….. 170
Figure 18 Application Segment Growth Rates …………………………………………………………………. 171
Figure 19 Segment Share Shifts ……………………………………………………………………………………….. 172
Figure 20 Application Segment Share Base Year …………………………………………………………….. 173
Figure 21 Application Segment Share Final Year ……………………………………………………………… 174
Figure 22 Technology Share by Year……………………………………………………………………………….. 176
Figure 23 Technology Segment Growth Rates …………………………………………………………………. 177
Figure 24 Technology Segment Share Shifts …………………………………………………………………….. 178
Figure 25 Technology Segment Share Base Year …………………………………………………………….. 179
Figure 26 Technology Segment Share Final Year ……………………………………………………………… 180
Figure 27 Product Share by Year …………………………………………………………………………………….. 182
Figure 28 Product Segment Growth Rates ………………………………………………………………………. 183
Figure 29 Product Segment Share Shifts ………………………………………………………………………….. 184
Figure 30 Product Segment Share Base Year …………………………………………………………………… 185
Figure 31 Product Segment Share Final Year …………………………………………………………………… 186
Figure 32 User Share by Year ………………………………………………………………………………………….. 188
Figure 33 User Segment Growth Rates …………………………………………………………………………….. 189
Figure 34 User Segment Share Shifts ………………………………………………………………………………… 190
Figure 35 User Segment Share Base Year ………………………………………………………………………… 191
Figure 36 User Segment Share Final Year …………………………………………………………………………. 192
Figure 37 Clinical vs. Total Market Growth ……………………………………………………………………….. 195
Figure 38 Microbiome vs. Total Market Growth ………………………………………………………………… 197
Figure 39 Agriculture vs. Total Market Growth ………………………………………………………………….. 199
Figure 40 Industrial & Other vs. Total Market Growth ………………………………………………………… 201
Figure 41 16srRNA vs. Total Market Growth………………………………………………………………………. 204
Figure 42 Shotgun vs. Total Market Growth ……………………………………………………………………… 206
Figure 43 WGS vs. Total Market Growth …………………………………………………………………………… 208
Figure 44 Other Technology vs. Total Market Growth ………………………………………………………. 210
Figure 45 Instrument vs. Total Market Growth …………………………………………………………………… 213
Figure 46 Reagents and Kits vs. Total Market Growth ……………………………………………………….. 215
Figure 47 Software vs. Total Market Growth …………………………………………………………………….. 217
Figure 48 Services vs. Total Market Growth ……………………………………………………………………… 219
Figure 49 Academic vs. Total Market Growth ………………………………………………………………….. 222
Figure 50 Clinical vs. Total Market Growth ……………………………………………………………………….. 224
Figure 51 Pharmaceutical vs. Total Market Growth ………………………………………………………….. 226
Figure 52 Other User Growth …………………………………………………………………………………………… 228
Profiles of Key Players
Arc Bio
BaseClear
BGI Genomics Co.
Biome Makers
bioMérieux Diagnostics
Bio-Rad Laboratories Inc
CosmosID
Element Biosciences
Fusion Genomics
Helix OpCo
Illumina
Institute for Metagenomics
Karius
Metabiomics Corp
Metagenomi
MetaSUB International Consortium
Microbiome Insights
MicroGenDx
Molecular Stethoscope
Norgen Biotek Corp.
Noscendo
Novogene Bioinformatics Technology
One Codex
OraSure Technologies
Oxford Nanopore Technologies
Pacific Biosciences
PathoQuest S.A.
Perkin Elmer
Promega
Qiagen
Second Genome
Siemens Healthineers
Sysmex
Takara Bio
Ultima Genomics
Zymo Research Corp
Table of Tables
Table 1 The Base Pairs………………………………………………………………………………………………………. 37
Table 2 Market Players by Type ……………………………………………………………………………………….. 43
Table 3 The Different Applications of Metagenomic Testing ………………………………………………. 49
Table 4 Factors Driving Growth …………………………………………………………………………………………. 57
Table 5 Four Factors Limiting Growth ………………………………………………………………………………… 62
Table 6 Seven Key Diagnostic Laboratory Technology Trends ……………………………………………. 65
Table 7 Global Market by Country ………………………………………………………………………………….. 167
Table 8 Global Market by Application ……………………………………………………………………………. 169
Table 9 Global Market by Technology ……………………………………………………………………………. 175
Table 10 Global Market by Product ………………………………………………………………………………… 181
Table 11 Global Market by User ……………………………………………………………………………………… 187
Table 12 Clinical Segment by Country ……………………………………………………………………………. 194
Table 13 Microbiome Segment by Country …………………………………………………………………….. 196
Table 14 Agriculture Segment by Country ………………………………………………………………………. 198
Table 15 Industrial & Other Segment by Country ……………………………………………………………… 200
Table 16 16srRNA Segment by Country …………………………………………………………………………… 203
Table 17 Shotgun Segment by Country …………………………………………………………………………… 205
Table 18 WGS Segment by Country ………………………………………………………………………………… 207
Table 19 Other Technology Segment by Country ……………………………………………………………. 209
Table 20 Instruments Segment by Country ………………………………………………………………………. 212
Table 21 Reagents and Kits Segment by Country ……………………………………………………………. 214
Table 22 Software Segment by Country ………………………………………………………………………….. 216
Table 23 Services Segment by Country …………………………………………………………………………… 218
Table 24 Academic Segment by Country ……………………………………………………………………….. 221
Table 25 Clinical Segment by Country ……………………………………………………………………………. 223
Table 26 Pharmaceutical Segment by Country ……………………………………………………………….. 225
Table 27 Other User Segment by Country ……………………………………………………………………….. 227
Table 28 Clinical Lab Fee Schedule ………………………………………………………………………………… 229
Table 29 The Most Common Assays ………………………………………………………………………………… 352
Table 30 Largest Revenue Assays ……………………………………………………………………………………. 357
Table of Figures
Figure 1 Global Health Care Spending ……………………………………………………………………………… 31
Figure 2 The Lab Test Pie ………………………………………………………………………………………………….. 32
Figure 3 DNA Strands and Chromosomes …………………………………………………………………………. 34
Figure 4 Karyogram of Human Chromosomes …………………………………………………………………… 35
Figure 5 Size of Various Genomes …………………………………………………………………………………….. 38
Figure 6 The Road to Diagnostics ……………………………………………………………………………………… 42
Figure 7 The New Diagnostics …………………………………………………………………………………………… 58
Figure 8 The Changing Age of the World Population …………………………………………………………. 59
Figure 9 Health Care Consumption by Age ………………………………………………………………………. 60
Figure 10 Cancer Incidence – Age at Diagnosis ………………………………………………………………… 60
Figure 11 Centralized vs. Decentralized Laboratory Service ………………………………………………. 66
Figure 12 A Highly Multiplexed Syndromic Testing Unit ……………………………………………………….. 66
Figure 13 The Real Cost to Sequence the Human Genome ……………………………………………….. 69
Figure 14 The Codevelopment Process …………………………………………………………………………….. 71
Figure 15 Comparing MDx Diagnostic and Traditional Testing ……………………………………………. 73
Figure 16 Country Market Shares …………………………………………………………………………………….. 168
Figure 17 Application Share by Year ……………………………………………………………………………….. 170
Figure 18 Application Segment Growth Rates …………………………………………………………………. 171
Figure 19 Segment Share Shifts ……………………………………………………………………………………….. 172
Figure 20 Application Segment Share Base Year …………………………………………………………….. 173
Figure 21 Application Segment Share Final Year ……………………………………………………………… 174
Figure 22 Technology Share by Year……………………………………………………………………………….. 176
Figure 23 Technology Segment Growth Rates …………………………………………………………………. 177
Figure 24 Technology Segment Share Shifts …………………………………………………………………….. 178
Figure 25 Technology Segment Share Base Year …………………………………………………………….. 179
Figure 26 Technology Segment Share Final Year ……………………………………………………………… 180
Figure 27 Product Share by Year …………………………………………………………………………………….. 182
Figure 28 Product Segment Growth Rates ………………………………………………………………………. 183
Figure 29 Product Segment Share Shifts ………………………………………………………………………….. 184
Figure 30 Product Segment Share Base Year …………………………………………………………………… 185
Figure 31 Product Segment Share Final Year …………………………………………………………………… 186
Figure 32 User Share by Year ………………………………………………………………………………………….. 188
Figure 33 User Segment Growth Rates …………………………………………………………………………….. 189
Figure 34 User Segment Share Shifts ………………………………………………………………………………… 190
Figure 35 User Segment Share Base Year ………………………………………………………………………… 191
Figure 36 User Segment Share Final Year …………………………………………………………………………. 192
Figure 37 Clinical vs. Total Market Growth ……………………………………………………………………….. 195
Figure 38 Microbiome vs. Total Market Growth ………………………………………………………………… 197
Figure 39 Agriculture vs. Total Market Growth ………………………………………………………………….. 199
Figure 40 Industrial & Other vs. Total Market Growth ………………………………………………………… 201
Figure 41 16srRNA vs. Total Market Growth………………………………………………………………………. 204
Figure 42 Shotgun vs. Total Market Growth ……………………………………………………………………… 206
Figure 43 WGS vs. Total Market Growth …………………………………………………………………………… 208
Figure 44 Other Technology vs. Total Market Growth ………………………………………………………. 210
Figure 45 Instrument vs. Total Market Growth …………………………………………………………………… 213
Figure 46 Reagents and Kits vs. Total Market Growth ……………………………………………………….. 215
Figure 47 Software vs. Total Market Growth …………………………………………………………………….. 217
Figure 48 Services vs. Total Market Growth ……………………………………………………………………… 219
Figure 49 Academic vs. Total Market Growth ………………………………………………………………….. 222
Figure 50 Clinical vs. Total Market Growth ……………………………………………………………………….. 224
Figure 51 Pharmaceutical vs. Total Market Growth ………………………………………………………….. 226
Figure 52 Other User Growth …………………………………………………………………………………………… 228
Since 2001 Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. We publish market research reports that address scientific industries with an emphasis on Biotechnology, Medical Imaging, Pharmaceutical and Clinical Diagnostic markets. We consider ourselves experts in these areas. This contrasts with the many research mills that produce canned reports on the Handbag market one day and the X-ray market the next.
We approach market research differently than other companies. At any one time we have a limited number of reports and we update them two to four times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area.
Our service goes beyond research reports. We often provide, at no extra cost, information that will help you apply our numbers to your unique situation. We’ve been doing this for years. Buying more than one report at a time can provide significant savings and upgraded licensing.
Our reports are sold on a 12 Month Subscription basis. Buying a report entitles you to the original current report plus an additional 1 to 3 follow on updated reports. At least one of these will include numbers and forecasts with an additional year. These reports are sent to you directly as they are released. This allows you to stay current on the situation and outlook in your area of interest. Your initial subscription can be renewed at a significantly discounted rate so that you can continue to keep on top of market developments. This program allows you to follow very specific market areas in detail in an ongoing and cost-effective way.
